(Q38096490)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

title

Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Anna Morena D'Alise

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

7

Antonella Folgori

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

author name string

Virginia Ammendola

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Stefano Colloca

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Riccardo Cortese

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

Alfredo Nicosia

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

publication date

1 April 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

28 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

page(s)

379-393

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

Features of responding T cells in cancer and chronic infection.

28 February 2020

cites work

1 reference

Immune-correlates analysis of an HIV-1 vaccine efficacy trial

21 January 2018

1 reference

CD8(+) T cells in preventing HIV infection and disease

21 January 2018

1 reference

Vaccine-induced CD8+ T cells control AIDS virus replication

21 January 2018

1 reference

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

21 January 2018

1 reference

Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety

21 January 2018

1 reference

Smallpox vaccines: Past, present, and future

21 January 2018

1 reference

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

21 January 2018

1 reference

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

21 January 2018

1 reference

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

21 January 2018

1 reference

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

21 January 2018

1 reference

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans

21 January 2018

1 reference

Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

21 January 2018

1 reference

Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

21 January 2018

1 reference

Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants

21 January 2018

1 reference

A DNA prime-modified vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge.

21 January 2018

1 reference

Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2

21 January 2018

1 reference

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

21 January 2018

1 reference

Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime-boost immunisation in non-human primates

21 January 2018

1 reference

A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge

21 January 2018

1 reference

Vaccination with Venezuelan equine encephalitis replicons encoding cowpox virus structural proteins protects mice from intranasal cowpox virus challenge

21 January 2018

1 reference

Alphavirus replicon particles as candidate HIV vaccines

21 January 2018

1 reference

Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers.

21 January 2018

1 reference

Phase I safety and immunogenicity evaluations of an alphavirus replicon HIV-1 subtype C gag vaccine in healthy HIV-1-uninfected adults

21 January 2018

1 reference

Viruses as vaccine vectors for infectious diseases and cancer

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector

21 January 2018

1 reference

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

21 January 2018

1 reference

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine

21 January 2018

1 reference

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

21 January 2018

1 reference

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

21 January 2018

1 reference

Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

21 January 2018

1 reference

Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial

21 January 2018

1 reference

An Ad5-vectored HIV-1 vaccine elicits cell-mediated immunity but does not affect disease progression in HIV-1-infected male subjects: results from a randomized placebo-controlled trial (the Step study)

21 January 2018

1 reference

Baseline Ad5 serostatus does not predict Ad5 HIV vaccine-induced expansion of adenovirus-specific CD4+ T cells

21 January 2018

1 reference

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

21 January 2018

1 reference

Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults

21 January 2018

1 reference

Adenovirus-5-vectored P. falciparum vaccine expressing CSP and AMA1. Part B: safety, immunogenicity and protective efficacy of the CSP component

21 January 2018

1 reference

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses

21 January 2018

1 reference

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

21 January 2018

1 reference

Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys

21 January 2018

1 reference

Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys

21 January 2018

1 reference

Novel adenovirus vector-based vaccines for HIV-1

21 January 2018

1 reference

International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations

21 January 2018

1 reference

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

21 January 2018

1 reference

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

21 January 2018

1 reference

Adenovirus serotype 26 utilizes CD46 as a primary cellular receptor and only transiently activates T lymphocytes following vaccination of rhesus monkeys

21 January 2018

1 reference

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

21 January 2018

1 reference

Adenovirus serotype 5 hexon mediates liver gene transfer

21 January 2018

1 reference

Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys

21 January 2018

1 reference

Vaccination with adenovirus serotypes 35, 26, and 48 elicits higher levels of innate cytokine responses than adenovirus serotype 5 in rhesus monkeys

21 January 2018

1 reference

Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species

21 January 2018

1 reference

Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge

21 January 2018

1 reference

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

21 January 2018

1 reference

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults

21 January 2018

1 reference

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults

21 January 2018

1 reference

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)

21 January 2018

1 reference

Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy

21 January 2018

1 reference

Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa

21 January 2018

1 reference

Creation of a panel of vectors based on ape adenovirus isolates

21 January 2018

1 reference

Replication-defective vector based on a chimpanzee adenovirus

21 January 2018

1 reference

A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity

21 January 2018

1 reference

Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates

21 January 2018

1 reference

A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines

21 January 2018

1 reference

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

21 January 2018

1 reference

Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein

21 January 2018

1 reference

Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei

21 January 2018

1 reference

Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens

21 January 2018

1 reference

A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.

21 January 2018

1 reference

Human immunodeficiency virus type 1-specific immune responses in primates upon sequential immunization with adenoviral vaccine carriers of human and simian serotypes

21 January 2018

1 reference

New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1

21 January 2018

1 reference

Prime-boost immunization with adenoviral and modified vaccinia virus Ankara vectors enhances the durability and polyfunctionality of protective malaria CD8+ T-cell responses

21 January 2018

1 reference

Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes

21 January 2018

1 reference

A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus

21 January 2018

1 reference

Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus

21 January 2018

1 reference

Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man.

21 January 2018

1 reference

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors

21 January 2018

1 reference

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector

21 January 2018

1 reference

Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial

21 January 2018

1 reference

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

21 January 2018

1 reference

Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults

21 January 2018

1 reference

A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals

21 January 2018

1 reference

Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria

21 January 2018

1 reference

Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya

21 January 2018

1 reference

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

21 January 2018

1 reference

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans

21 January 2018

1 reference

A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees

21 January 2018

1 reference

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

21 January 2018

1 reference

The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response

21 January 2018

1 reference

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

21 January 2018

1 reference

Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy.

21 January 2018

1 reference

Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein

21 January 2018

1 reference

A candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses

21 January 2018

1 reference

Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara

21 January 2018

1 reference

Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic caspase pathways, preventing efficient antigen presentation.

21 January 2018

1 reference

Vaccination with Ad5 vectors expands Ad5-specific CD8 T cells without altering memory phenotype or functionality

21 January 2018

1 reference

Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy

21 January 2018

1 reference

Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells

21 January 2018

1 reference

The CD4+ T-cell response to adenovirus is focused against conserved residues within the hexon protein

21 January 2018

1 reference

Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine

21 January 2018

1 reference

Adenovirus-specific human T cells are pervasive, polyfunctional, and cross-reactive

21 January 2018

1 reference

Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines

21 January 2018

1 reference

Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors.

21 January 2018

1 reference

Avian cell line - Technology for large scale vaccine production

21 January 2018

1 reference

New avian suspension cell lines provide production of influenza virus and MVA in serum-free media: studies on growth, metabolism and virus propagation

21 January 2018

1 reference

Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass

21 January 2018

1 reference

Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules.

21 January 2018

1 reference

Devices for intradermal vaccination

21 January 2018

1 reference

Coated microneedle arrays for transcutaneous delivery of live virus vaccines

21 January 2018

1 reference

Potential of Nasopharynx-associated Lymphoid Tissue for Vaccine Responses in the Airways

21 January 2018

1 reference

Vaccination strategies for mucosal immune responses

21 January 2018

1 reference

Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices

21 January 2018

1 reference

Development of adenoviral vector-based mucosal vaccine against influenza

21 January 2018

1 reference

Adenovirus-vectored drug-vaccine duo as a potential driver for conferring mass protection against infectious diseases

21 January 2018

1 reference

Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans.

21 January 2018

1 reference

A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya

21 January 2018

1 reference

A randomised, double-blind, controlled vaccine efficacy trial of DNA/MVA ME-TRAP against malaria infection in Gambian adults

21 January 2018

1 reference

Long peptides induce polyfunctional T cells against conserved regions of HIV-1 with superior breadth to single-gene vaccines in macaques.

21 January 2018

1 reference

Therapeutic vaccination against chronic hepatitis C virus infection

21 January 2018

1 reference

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERV.13.15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23560919%20AND%20SRC:MED&resulttype=core&format=json

28 February 2020

1 reference